Organon Q2 revenue $1.594B, adj. EPS $1.00; raises FY revenue guidance to $6.275-6.375B

Organon & Co.

2025-Q2 EPS reported $0.89 revenue$3,107,000,000

Revenue $1.594B, down 1% YoY; GAAP net income $145M ($0.56 EPS); non-GAAP adj. EPS $1.00, down 11% YoY.
Adjusted EBITDA $522M (32.7% margin) vs $513M (31.9%) prior year; repaid $345M of long-term debt in Q2.
Women's Health revenue up 2% ex-FX; fertility business +15% ex-FX; Nexplanon flat ex-FX.
Biosimilars up 6% ex-FX (Hadlima growth); Established Brands down 4% ex-FX on Atozet LOE in Europe.
FY 2025 revenue guidance raised to $6.275-6.375B; adj. EBITDA margin guidance affirmed at 31-32%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.